Fritextsökning
Innehållstyper
-
Positive EMA Decision for BioArctic's New Drug Candidate
Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).
-
Setback for pharmaceutical companies in the Zantac case
A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.
-
Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients
In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.
-
Ossiform: Quality control of 3D printed bone implants
Ossiform chose the GOM Scan 1.
-
Automated opening and closing of sample vials
From technical requirements to a suitable solution
-
A new scientific event in Gothenburg
Life Science Sweden is holding an event in Gothenburg for the first time.
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...
-
Assignment: Facilitate the retention of foreign researchers
A newly appointed public inquiry is to develop measures to make attracting and retaining foreign doctoral students and researchers in Sweden easier.
-
Column: ”Life as a F1 race”
"The F1 car makes several pit stops during a race and during a lifetime the human being may also have to come in several times for maintenance", Björn Ursing wr...
-
Explore the latest trends and innovations in quality assurance and manufacturing
ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.
-
The dock that “thinks” for itself
The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...
-
The new Swedish life science strategy – “It will consolidate Sweden as a leader”
Clinical trials and precision health are emphasised as key areas in the new national life science strategy.
-
ZEISS Quality Innovation Days: April 15 – 19, 2024
Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.
-
Success for Genmab's antibody-drug conjugate
The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
-
ZEISS receives FDA clearance for INTRABEAM 700
With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.
-
One last chance to register for the premier metrology event in 2024
ZEISS QUALITY INNOVATION SUMMIT.
-
He got inside the head of Sweden’s vaccine hunter
The hunt for the COVID-19 vaccine is the theme of the new book Vaccinjägaren (The Vaccine Hunter). It tells the story of Richard Bergström’s mission as Sweden’s...
-
Quality Assurance for the Highest Medical Standards
Metrology Solutions for Medical Components.
-
Automated dispensing of a viscous hydrogel
A suitable solution developed for UPM Biomedicals In the Festo LifeTech Application Center we tested a setup for UPM Biomedicals for the automatic dispensing of...
-
KI-bolag får stöd av Michael J. Fox Foundation
Svenska Umecrine Cognition har fått ett anslag från The Michael J. Fox Foundation för att utvärdera bolagets läkemedelskandidat golexanolon som behandling för P...
-
New large lab building in Lund inaugurated – here are the companies moving in
Medicon Village has received a new laboratory building. On Friday last week the building was inaugurated with a ribbon-cutting ceremony by Minister for Employme...
-
Ozempic may benefit hip replacement surgery
The high-profile drug for type 2 diabetes and weight loss may be beneficial in other areas. One such area is for patients undergoing hip replacement surgery, a ...
-
100 years of Festo
The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...
-
From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”
A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...